| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
-Melanocyte-stimulating Hormone Receptors in Human and Mouse Melanoma Cell Lines1
Laboratory of Endocrinology, Department of Research (ZLF), University Hospital and University Children's Hospital, Ch-4031 Basel, Switzerland
Specific high-affinity receptors for
-melanocyte-stimulating hormone (
-MSH) are found in variable abundance on many melanoma cell lines. We have examined melanocortin peptides and other factors for their ability to regulate the number of MSH receptors in eleven human and two mouse melanoma cell lines. MSH induced up-regulation of its own receptors in three human cell lines and down-regulation in six human and two mouse melanoma cell lines. No regulation was observed in two human lines. Scatchard analysis revealed modulation of the number of receptors per cell without any change in affinity. The concentrations inducing half-maximal response for up- and down-regulation were 1.6 nM and 0.23 nM, respectively. ACTH117 and [Nle4,D-Phe7]-
-MSH were more potent, whereas ACTH124, desacetyl-
-MSH, and [Nle4]-
-MSH were less potent in receptor up-regulation as compared to
-MSH. Down-regulation but not up-regulation could be fully mimicked by Gs-protein activation and partially by elevation of cellular cAMP. Combination of different agents which increase cAMP was found to be counterregulatory. TPA and retinoic acid generally down-regulated MSH receptors but had no effect on HBL cells. Several protein kinase inhibitors increased MSH binding in B16 cells. MSH-induced receptor down-regulation and melanin synthesis were most effectively antagonized by selective inhibitors of cAMP-dependent protein kinase in these cells. Taken together, MSH receptors on melanoma cells are both positively and negatively regulated. Whereas cAMP-dependent protein kinase activation seems to be involved in down-regulation, the mechanism responsible for up-regulation remains to be elucidated.
1 Presented in preliminary forms at the 9th International Congress of Endocrinology, August 30September 5, 1992, Nice, France, and at the 5th Swiss Workshop of Methodology in Receptor Research, May 1014, 1992, Agno-Lugano, Switzerland. This work was supported by the Swiss National Science Foundation (Grant 3100-25653), the Swiss Cancer League, and the Fund of the Department of Research.
2 To whom reprint requests should be addressed.
Received 12/ 3/93. Accepted 3/17/94.
This article has been cited by other articles:
![]() |
G. Ren, Z. Liu, Z. Miao, H. Liu, M. Subbarayan, F. T. Chin, L. Zhang, S. S. Gambhir, and Z. Cheng PET of Malignant Melanoma Using 18F-Labeled Metallopeptides J. Nucl. Med., November 1, 2009; 50(11): 1865 - 1872. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Beaumont, S. L. Shekar, R. A. Newton, M. R. James, J. L. Stow, D. L. Duffy, and R. A. Sturm Receptor function, dominant negative activity and phenotype correlations for MC1R variant alleles Hum. Mol. Genet., September 15, 2007; 16(18): 2249 - 2260. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Cheng, L. Zhang, E. Graves, Z. Xiong, M. Dandekar, X. Chen, and S. S. Gambhir Small-Animal PET of Melanocortin 1 Receptor Expression Using a 18F-Labeled {alpha}-Melanocyte-Stimulating Hormone Analog J. Nucl. Med., June 1, 2007; 48(6): 987 - 994. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Schwarz, D. Renshaw, S. Kapas, and J. P Hinson Adrenomedullin increases the expression of calcitonin-like receptor and receptor activity modifying protein 2 mRNA in human microvascular endothelial cells. J. Endocrinol., August 1, 2006; 190(2): 505 - 514. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Beaumont, R. A. Newton, D. J. Smit, J. H. Leonard, J. L. Stow, and R. A. Sturm Altered cell surface expression of human MC1R variant receptor alleles associated with red hair and skin cancer risk Hum. Mol. Genet., August 1, 2005; 14(15): 2145 - 2154. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sanchez-Mas, L. A. Guillo, P. Zanna, C. Jimenez-Cervantes, and J. C. Garcia-Borron Role of G Protein-Coupled Receptor Kinases in the Homologous Desensitization of the Human and Mouse Melanocortin 1 Receptors Mol. Endocrinol., April 1, 2005; 19(4): 1035 - 1048. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Chen, Z. Cheng, N. K. Owen, T. J. Hoffman, Y. Miao, S. S. Jurisson, and T. P. Quinn Evaluation of an 111In-DOTA-Rhenium Cyclized {alpha}-MSH Analog: A Novel Cyclic-Peptide Analog with Improved Tumor-Targeting Properties J. Nucl. Med., December 1, 2001; 42(12): 1847 - 1855. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Chen, Z. Cheng, T. J. Hoffman, S. S. Jurisson, and T. P. Quinn Melanoma-targeting Properties of 99mTechnetium-labeled Cyclic {{alpha}}-Melanocyte-stimulating Hormone Peptide Analogues Cancer Res., October 1, 2000; 60(20): 5649 - 5658. [Abstract] [Full Text] |
||||
![]() |
S. Adachi, E. Morii, D.-k. Kim, H. Ogihara, T. Jippo, A. Ito, Y.-M. Lee, and Y. Kitamura Involvement of mi-Transcription Factor in Expression of {alpha}-Melanocyte-Stimulating Hormone Receptor in Cultured Mast Cells of Mice J. Immunol., January 15, 2000; 164(2): 855 - 860. [Abstract] [Full Text] [PDF] |
||||
![]() |
J Chluba-de Tapia, C Bagutti, R Cotti, and A. Eberle Induction of constitutive melanogenesis in amelanotic mouse melanoma cells by transfection of the human melanocortin-1 receptor gene J. Cell Sci., January 8, 1996; 109(8): 2023 - 2030. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |